Bank of New York Mellon
DYN icon

Bank of New York Mellon’s Dyne Therapeutics DYN Stock Holding History

Bank of New York Mellon’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.1M Buy
409,801
+8,185
+2% +$152K ﹤0.01% 2081
2026
Q1 		$7.28M Buy
401,616
+48,119
+14% +$830K ﹤0.01% 2098
2025
Q4 		$6.91M Buy
353,497
+36,133
+11% +$684K ﹤0.01% 2132
2025
Q3 		$4.01M Buy
317,364
+47,700
+18% +$544K ﹤0.01% 2452
2025
Q2 		$2.57M Buy
269,664
+37,038
+16% +$408K ﹤0.01% 2625
2025
Q1 		$2.43M Sell
232,626
-2,172
-0.9% -$31.1K ﹤0.01% 2594
2024
Q4 		$5.53M Buy
234,798
+698
+0.3% +$20.6K ﹤0.01% 2239
2024
Q3 		$8.41M Sell
234,100
-77,404
-25% -$3.08M ﹤0.01% 2023
2024
Q2 		$11M Buy
311,504
+107,233
+52% +$3.12M ﹤0.01% 1907
2024
Q1 		$5.8M Buy
204,271
+33,711
+20% +$762K ﹤0.01% 2252
2023
Q4 		$2.27M Buy
170,560
+13,117
+8% +$128K ﹤0.01% 2759
2023
Q3 		$1.41M Buy
157,443
+7,196
+5% +$77.5K ﹤0.01% 2994
2023
Q2 		$1.69M Buy
150,247
+23,384
+18% +$276K ﹤0.01% 2932
2023
Q1 		$1.46M Sell
126,863
-432
-0.3% -$5.61K ﹤0.01% 2967
2022
Q4 		$1.48M Buy
127,295
+7,729
+6% +$89.4K ﹤0.01% 3008
2022
Q3 		$1.52M Buy
119,566
+10,065
+9% +$115K ﹤0.01% 2999
2022
Q2 		$752K Sell
109,501
-2,586
-2% -$17.8K ﹤0.01% 3342
2022
Q1 		$1.08M Sell
112,087
-3,860
-3% -$32.9K ﹤0.01% 3259
2021
Q4 		$1.38M Sell
115,947
-289,315
-71% -$4.07M ﹤0.01% 3201
2021
Q3 		$6.58M Buy
405,262
+15,654
+4% +$278K ﹤0.01% 2357
2021
Q2 		$8.2M Buy
389,608
+152,461
+64% +$2.87M ﹤0.01% 2247
2021
Q1 		$3.68M Buy
237,147
+86,914
+58% +$1.68M ﹤0.01% 2594
2020
Q4 		$3.15M Buy
150,233
+48,006
+47% +$950K ﹤0.01% 2583
2020
Q3 		$2.06M Buy
+102,227
New +$2.24M ﹤0.01% 2648

Other funds holding DYN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Bank of New York Mellon's DYN Position: Q2 2026 in Review

Bank of New York Mellon increased its Dyne Therapeutics (DYN) stake by 2% in Q2 2026, buying an estimated $152K and bringing the position to 409,801 shares worth $9.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2081.

Bank of New York Mellon first reported a position in DYN in Q3 2020 and has held it in 24 quarters since. The position peaked at $11M in Q2 2024. 83 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Bank of New York Mellon held 409,801 shares of Dyne Therapeutics worth $9.1M as of Q2 2026.
  • Bank of New York Mellon bought 8,185 Dyne Therapeutics shares in Q2 2026, an estimated $152K.
  • Dyne Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2081 holding.
  • Bank of New York Mellon first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Bank of New York Mellon's Dyne Therapeutics position peaked at $11M in Q2 2024.
  • 83 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.